RecruitingNot ApplicableNCT05647733

Restrictive Fluid Management In Liver Transplantation (REFIL)

Effects of an Intraoperative Low-splanchnic Blood Volume Restrictive Fluid Management Strategy Compared to a Cardiac Output Optimized Liberal Fluid Management Strategy on Postoperative Outcomes in Liver Transplantation


Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Enrollment

138 participants

Start Date

Apr 25, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Hypothesis: A Canadian multicentre clinical trial is feasible. Study Design: Multicenter internal pilot parallel arm randomized controlled trial. Study population: Patients with end-stage liver disease (ESLD) undergoing a liver transplantation, not meeting any exclusion criteria. Primary feasibility endpoint: An overall recruitment rate ≥ 4 patients/month across all four participating sites. Secondary feasibility endpoints: A protocol adherence \> 90%, a 30-day (or hospital discharge) and 6-month outcome measurement \> 90%, and a mean difference in total intraoperative volume received (crystalloids and colloids combined) \> 1000 ml between groups. Study intervention: Low splanchnic blood volume restrictive fluid management strategy (intervention). A phlebotomy, performed prior to dissection and transfused back after graft reperfusion, combined with a hemodynamic goal-directed restrictive fluid management strategy. Optimized cardiac-output liberal fluid management strategy (control) A hemodynamic goal-directed liberal fluid management strategy that optimizes cardiac output throughout surgery.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • Any adult patient ≥ 18 years of age undergoing liver transplantation for ESLD.

Exclusion Criteria6

  • Patients undergoing LT for an indication other than ESLD such as acute liver failure, liver cancer without ESLD, retransplantation, amyloid neuropathy or any other indication not associated with ESLD.
  • Patients undergoing a combined liver and lung or liver and heart transplantation.
  • Patients with any of the following conditions:
  • severe chronic renal failure (GFR \< 15 ml/minute/1.73 m2 \[CKD-EPI equation\] or already on RRT);
  • severe anemia (hemoglobin level \< 80 g/L);76,93,109
  • hemodynamic instability (norepinephrine equivalent \> 10 ug/min).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURELow splanchnic blood volume restrictive fluid management strategy

Hemodynamic goal-directed restrictive fluid management strategy

PROCEDUREOptimized cardiac output liberal fluid management strategy

Permissive hemodynamic goal-directed fluid management strategy that optimizes cardiac output throughout surgery

PROCEDUREPhlebotomy

Retrieval of blood in a blood donation bag performed prior to dissection and transfused back after graft reperfusion


Locations(4)

Vancouver General Hospital

Vancouver, British Columbia, Canada

London Health Sciences Centre

London, Ontario, Canada

Centre Hospitalier de l'Université de Montréal (CHUM)

Montreal, Quebec, Canada

McGill University Health Centre

Montreal, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05647733


Related Trials